| As of Wednesday, November 25th: |
LATEST EARNINGS RESULTS
- Dubai Seeks Debt Delay, Stokes Default Fears
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- The Executive Job Search
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Where Do Pardoned Turkeys Go?
- Salvation Army's Kettles Now Credit Card-Ready
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Trader Talk
- Black Friday: Bargain or Bust?
- Wal-Mart Price Pressure Hurts China Workers: Report
Text Size 
Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
"Lilly had top-line strength across its portfolio, with each major therapeutic segment above our outlook," said Bear Stearns analyst John Boris. He noted the company's tax rate of
20.4 percent was less than his 22 percent forecast.
The Indianapolis-based drugmaker earned $854 million, or 78 cents per share. That compared with $132 million, or 12 cents per share, in the year-ago period, when Lilly took a big charge for a settlement with patients who claimed to have been harmed by its Zyprexa schizophrenia drug.
Top company officials remain upbeat about the future, despite signs of a softening economy.
"I'm not sure we can claim that our business is recession-proof, completely, but we stand by our guidance of double-digit earnings per share growth between now and 2011, compounded," Eli Lilly President & COO John Lechleiter told CNBC.
Lechleiter is scheduled to become the company's CEO on April 1.
Excluding special items, earnings rose 6 percent to 90 cents per share. Analysts on average had expected 89 cents per share, according to Reuters Estimates. The company took two charges, totaling 12 cents per share, related largely to restructuring and acquisitions.
Company global sales jumped 22 percent in the quarter to $5.19 billion, ahead of the Reuters Estimates forecast of $4.81 billion. Sales would have grown by 18 percent if not for the weak dollar, which boosts the value of overseas sales.
Sales of Zyprexa rose 10 percent to $1.27 billion, in a continuing rebound from earlier declines that had been sparked by concerns that the drug causes weight gains which raise diabetes risk.
Revenue from impotence treatment Cialis, which works far longer than Pfizer's Viagra and was recently approved in a new low-dose daily formulation, jumped 29 percent to $346 million.
Sales of Alimta, used to treat tumors caused by exposure to asbestos, soared 42 percent to $244 million, helped by its other approved use against lung cancer. Sales of Gemzar, an older lung cancer drug, rose 15 percent to $426 million.
Injectable diabetes drug Byetta, sold in partnership with Amylin Pharmaceuticals, gained ground from its wide use alongside oral treatments and its ability to help patients lose weight. Its global sales soared 34 percent to $184 million.
Humalog, a rapid-acting insulin used at mealtimes, was also a top performer during the quarter. Its sales jumped 18 percent to $414 million, helped by price increases and sizzling growth in overseas markets.
Lilly [LLY
Loading...
()
] said it is on track to meet its 2008 earnings target, excluding special items, of $3.85 to $4 per share -- driven by growing demand for Cymbalta, Cialis, Byetta, Alimta and Humalog. That would reflect profit growth of 9 to 13 percent from 2007 results.
CNBC.com contributed to this article.
Print
Email
- TiVo Reports Quarterly Loss but Matches Forecasts
TiVo announced a quarterly loss that matched analysts' forecasts, but its sales topped expectations.
- Hewlett-Packard Profit Rises, Matches Guidance
Hewlett-Packard said a strong performance in China and improved profit margins in its services business helped drive quarterly earnings 14 percent higher.
- Analog Devices Results Beat Expectations; Shares Rise
Analog Devices reported a quarterly profit that fell from a year ago but topped Wall Street's expectations, sending shares higher in extended trading.
- TiVo Reports Quarterly Loss but Matches Forecasts
- Tyson Food Profit Beats Estimates
Tyson Foods posted higher-than-expected quarterly results on Monday on strength in its beef, pork and prepared foods businesses, which it expects to continue in its new fiscal year.
- Tyson Food Profit Beats Estimates
- Horton Results Miss Estimates, Shares Drop
- Dell Shares Smacked as Earnings, Sales Miss Forecasts
- Gap Reports Earnings in Line With Forecasts
- Intuit Posts Narrower-Than-Expected Loss
- Sears Posts Second Consecutive Quarterly Loss
- BJ's Wholesale Profit Falls, Hurt by Falling Food Prices
- Salesforce Profit Beats Forecasts, but Shares Fall
- Autodesk Shares Fall on Disappointing Outlook
- Home Depot Profit Beats; Says Markets Under Pressure
- Target Third Quarter Profit Up, Cautious on Fourth
- Weak US Housing Market Drags on Lowe's Profit
- JC Penney Profit Falls, but Shares Up on Forecast
- Disney Profit, Sales Top Forecasts; Shares Jump
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
- Wal-Mart Holiday Forecast Light, Profit Beats
Data is a real-time snapshot *Data is delayed at least 15 minutes